Compatibility of Melphalan in Iodinated Contrast Media
Author(s): Shi Zhanquan, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
Issue: Jan/Feb 2020 - Volume 24, Number 1
View All Articles in Issue
Page(s): 83-85
Download in electronic PDF format for $75
Abstract: Melphalan is used in selective ophthalmic artery infusion chemotherapy. In the procedure to catheterize the ophthalmic artery in selective ophthalmic artery infusion chemotherapy, the microcatheter is usually filled with an iodinated contrast medium. It is not known whether mixing of iodinated contrast medium with melphalan solutions promotes precipitation of melphalan during selective ophthalmic artery infusion chemotherapy. The objective of the present study was to examine the compatibility of melphalan and iodinated contrast medium. In the experiments, melphalan solutions were prepared with and without iodinated contrast medium (iohexol 300 mg Iodine/mL or ioversol 74%). Melphalan solution of clinically relevant concentration (0.45 mg/mL) in the absence of iodinated contrast medium was evaluated as a reference. The 0.45-mg/mL melphalan solution was diluted with iodinated contrast medium at 1:9 and 1:1 ratios to form solutions comprising iodinated contrast medium at 10% or 50% (v/v), and each was evaluated. The formation of particles was examined using filtration (pore size 0.45 µm) followed by high-performance liquid chromatography at four quarterly time intervals (15 min, 30 min, 45 min, and 60 min) over a 1-hour period after solution preparation. High-performance liquid chromatography analysis of microfiltered solutions did not reveal evidence of melphalan crystal formation over a 60-minute period for the solutions studied. The filtration studies suggest that mixing of the iodinated contrast medium with melphalan solutions does not result in significant melphalan precipitation.
Related Keywords:
Zhanquan Shi, PhD, Todd Abruzzo, MD, Apipa Wanasathop, BS, S. Kevin Li, PhD, melphalan, iodinated contrast media, selective ophthalmic artery infusion chemotherapy, SOAIC, intraocular retinoblastoma, compatibility
Related Categories:
CANCER AND AIDS, NUCLEAR, OPHTHALMICS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compatibility of Melphalan in Iodinated Contrast Media
Shi Zhanquan, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
|
Jan/Feb 2020
Pg. 83-85
|
Basics of Compounding for the Treatment of Warts
Allen Loyd V Jr
|
Mar/Apr 2004
Pg. 126-129
|
N-acetylcysteine Used to Decrease the Incidence of Contrast-Induced Nephropathy Following Radiographic Procedures: A Literature Review
McElhiney Linda F
|
Mar/Apr 2005
Pg. 99-103
|
Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device
Tsiouris Maria, Ulmer Marisa, Yurcho James F, Hooper Kevin L, Gui Min
|
Sep/Oct 2010
Pg. 436-439
|
Medium-Chain Triglycerides Oral Vehicle, Anhydrous
Allen Loyd V Jr
|
Jan/Feb 2006
Pg. 63
|
Anhydrous Medium-chain Triglycerides Gel
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 316
|
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials
Mueller Claudia, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
|
May/Jun 2015
Pg. 261-267
|
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump
Tomasello Cristina, Leggieri Anna, Rabbia Franco, Veglio Franco, Baietto Lorena, Fulcheri Chiara, De Nicolò Amedeo, De Perri Giovanni, D'Avolio Antonio
|
Jul/Aug 2016
Pg. 343-346
|
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 449-450
|
A Guide to Effective Media Relations
Walker Jennifer Klein
|
Mar/Apr 2002
Pg. 111-112
|
Xylitol in the Prevention of Otitis Media
Glasnapp Andrew
|
May/Jun 2000
Pg. 171-174
|
Acetylcysteine 200-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2007
Pg. 417
|
Acetylcysteine 200-mg Packets
Allen Loyd V Jr
|
Sep/Oct 2007
Pg. 418
|
Cinnarizine 1 mg/mL in Oral Medium-Chain Triglycerides Anhydrous Vehicle
Allen Loyd V Jr
|
May/Jun 2022
Pg. 236
|
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
|
May/Jun 2022
Pg. 248-254
|
Potassium Alum 1% Bladder Irrigation for Hemorrhagic Cystitis (Low-Medium Risk Compounding)
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 515
|
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 170-173
|
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 156-160
|
Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel
|
Jan/Feb 2009
Pg. 78-80
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Return to Top |